A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00404157 |
Recruitment Status
:
Withdrawn
First Posted
: November 27, 2006
Last Update Posted
: April 12, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lupus Nephritis | Drug: Rituximab | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Primary Purpose: | Treatment |
Official Title: | A Phase III, Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g |

- Safety will be monitored through regular physical examinations, vital signs, hematologic laboratory tests, urinalyses, and incidence and severity of adverse events.
- Proportion of subjects who maintain a CRR achieved at Week 52 in Study U2970g
- Serum rituximab levels
- Circulating B-cell counts.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 75 Years (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ability and willingness to provide written informed consent and comply with the requirements of the study protocol
- Participation in Study U2970g and completion of the Week 52 visit in that study
- For subjects of reproductive potential (males and females), use of a reliable means of contraception throughout their study participation
Exclusion Criteria:
- Discontinuation or withdrawal from Study U2970g or failure to complete the Week 52 visit
- Any safety concern potentially attributable to rituximab that in the investigator's opinion may jeopardize subject safety
- In the investigator's opinion, lack of any clinical improvement by Week 52 in Study U2970g and for whom the proposed therapy would represent risk without benefit
- Current thrombocytopenia or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or platelet transfusions
- Lack of peripheral venous access
- Pregnancy or lactation
- History of severe, allergic, or anaphylactic reactions to humanized or murine monoclonal antibodies
- Significant new or uncontrolled disease in any organ system not related to SLE (e.g., poorly controlled chronic obstructive pulmonary disease or asthma, cardiovascular disease, accelerated hypertension, major depression) that in the investigator's opinion would preclude subject participation
- Known active infection of any kind (excluding fungal infection of nail beds), any major episode of infection requiring hospitalization, or treatment with IV antibiotics within 4 weeks of a study drug infusion or oral antibiotics within 2 weeks of a study drug infusion
- History of cancer, including solid tumors, hematologic malignancies, and carcinoma in situ
- Major surgery within 4 weeks prior to screening
- Intolerance or contraindication to oral or IV corticosteroids
- Lipase > 2 x the upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x the ULN
- Amylase levels > 2 x the ULN
- Absolute neutrophil counts < 1.5 x 10^3/uL
- History of positive hepatitis B surface antigen or hepatitis C serology
- Hemoglobin < 7 g/dL unless caused by autoimmune hemolytic anemia resulting from SLE
- Platelet count < 10,000/uL
- Receipt of a live vaccine within 28 days prior to treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00404157
Study Director: | Jay Garg, M.D. | Genentech, Inc. |
Responsible Party: | Genentech, Inc. |
ClinicalTrials.gov Identifier: | NCT00404157 History of Changes |
Other Study ID Numbers: |
U3388g |
First Posted: | November 27, 2006 Key Record Dates |
Last Update Posted: | April 12, 2017 |
Last Verified: | April 2017 |
Keywords provided by Genentech, Inc.:
Lupus U2970g |
Additional relevant MeSH terms:
Nephritis Lupus Nephritis Kidney Diseases Urologic Diseases Glomerulonephritis Lupus Erythematosus, Systemic Connective Tissue Diseases |
Autoimmune Diseases Immune System Diseases Rituximab Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |